We are live on
!
Find out more
VEA
Virtus ETF Advisers Portfolio holdings
AUM
$215M
1-Year Est. Return
53.68%
This Fund
S&P 500
This Quarter
Est. Return
-1.04%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$165M
AUM Growth
-$4.08M
(-2.4%)
Cap. Flow
+$2.01M
Cap. Flow
% of AUM
1.22%
Top 10 Holdings %
Top 10 Hldgs %
6.09%
Holding
488
New
53
Increased
73
Reduced
307
Closed
54
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alphabet (Google) Class A
GOOGL
|
+$805K |
| 2 |
Halliburton
HAL
|
+$792K |
| 3 |
Caterpillar
CAT
|
+$787K |
| 4 |
Steel Dynamics
STLD
|
+$775K |
| 5 |
Booking.com
BKNG
|
+$775K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Netflix
NFLX
|
+$1.05M |
| 2 |
Vulcan Materials
VMC
|
+$1.01M |
| 3 |
CoStar Group
CSGP
|
+$998K |
| 4 |
Eli Lilly
LLY
|
+$967K |
| 5 |
Ingersoll Rand
IR
|
+$913K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 18.63% |
| 2 | Financials | 17.26% |
| 3 | Technology | 14.89% |
| 4 | Energy | 9.42% |
| 5 | Consumer Discretionary | 8.66% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MRUS
351
DELISTED
Merus
MRUS
| $88K | 0.05% |
3,731
-372
| -9% | -$9.02K |
|
352
Cytokinetics
CYTK
$10.6B
| $83.2K | 0.05% |
2,824
-282
| -9% | -$9.39K |
|
353
Alector
ALEC
$169M
| $83.1K | 0.05% |
12,831
-1,273
| -9% | -$8.24K |
|
|
SWTX
354
DELISTED
SpringWorks Therapeutics
SWTX
| $83K | 0.05% |
3,590
-356
| -9% | -$9.73K |
|
|
IGMS
355
DELISTED
IGM Biosciences
IGMS
| $82.7K | 0.05% |
9,909
-987
| -9% | -$8.37K |
|
356
Regenxbio
RGNX
$616M
| $82.7K | 0.05% |
5,025
-498
| -9% | -$9.03K |
|
357
Keros Therapeutics
KROS
$197M
| $81.6K | 0.05% |
2,561
-257
| -9% | -$9.59K |
|
358
Arbutus Biopharma
ABUS
$847M
| $81.3K | 0.05% |
40,040
-3,984
| -9% | -$8.35K |
|
359
Zentalis Pharmaceuticals
ZNTL
$332M
| $80.5K | 0.05% |
4,012
-403
| -9% | -$10.2K |
|
360
Phathom Pharmaceuticals
PHAT
$928M
| $80.3K | 0.05% |
7,744
-771
| -9% | -$10.6K |
|
361
Liquidia Corp
LQDA
$7.72B
| $79.7K | 0.05% |
12,566
-1,251
| -9% | -$9.01K |
|
362
Xenon Pharmaceuticals
XENE
$6.1B
| $79.4K | 0.05% |
2,324
-228
| -9% | -$8.53K |
|
363
Kura Oncology
KURA
$793M
| $78.7K | 0.05% |
8,624
-856
| -9% | -$8.69K |
|
|
AMAM
364
DELISTED
Ambrx Biopharma Inc
AMAM
| $78.1K | 0.05% |
6,793
-675
| -9% | -$9.19K |
|
|
RAPT
365
DELISTED
RAPT Therapeutics
RAPT
| $78K | 0.05% |
586
-58
| -9% | -$9.47K |
|
|
ITOS
366
DELISTED
iTeos Therapeutics
ITOS
| $77.4K | 0.05% |
7,066
-707
| -9% | -$9.04K |
|
367
Recursion Pharmaceuticals
RXRX
$1.58B
| $76.7K | 0.05% |
10,032
-996
| -9% | -$9.94K |
|
|
VERV
368
DELISTED
Verve Therapeutics
VERV
| $76.7K | 0.05% |
5,782
-577
| -9% | -$9.29K |
|
369
CRISPR Therapeutics
CRSP
$4.69B
| $76.3K | 0.05% |
1,681
-163
| -9% | -$8.42K |
|
370
Cullinan Oncology
CGEM
$1.06B
| $76.1K | 0.05% |
8,404
-835
| -9% | -$8.7K |
|
371
Zymeworks
ZYME
$1.62B
| $75.3K | 0.05% |
11,871
-1,183
| -9% | -$8.74K |
|
372
Arrowhead Research
ARWR
$12.1B
| $75.2K | 0.05% |
2,799
-278
| -9% | -$8.52K |
|
373
Cogent Biosciences
COGT
$6.76B
| $75.1K | 0.05% |
7,700
-762
| -9% | -$9.04K |
|
374
Xencor
XNCR
$1.45B
| $75K | 0.05% |
3,722
-375
| -9% | -$8.53K |
|
|
BCYC
375
Bicycle Therapeutics
BCYC
$269M
| $74.4K | 0.05% |
3,705
-369
| -9% | -$8.44K |
|
Similar funds
NCM
SSA
LIWM
VFG
IAM
1M
RC
TSS
Virtus ETF Advisers's Q3 2023 Portfolio in Review
As of Q3 2023, Virtus ETF Advisers held 488 positions worth $165M, down 2.4% from $169M the previous quarter. Its ten largest holdings account for 6.1% of the portfolio.
Virtus ETF Advisers's Q3 2023 filing shows 53 new, 73 increased, 307 reduced and 54 closed positions. Its largest new stake was Alphabet (Google) Class A: 6,222 shares worth $814K. The largest sale was Netflix, an estimated $1.05M.
By sector, the portfolio is most concentrated in Healthcare at 19% of assets, down from 28% a quarter earlier, followed by Financials and Technology.
- Virtus ETF Advisers's largest Q3 2023 buy was Alphabet (Google) Class A: 6,222 shares worth $814K.
- Virtus ETF Advisers added most to Coterra Energy in Q3 2023, an estimated $732K increase.
- Virtus ETF Advisers's biggest Q3 2023 reduction was Incyte, cutting an estimated $701K.
- Virtus ETF Advisers fully exited Netflix in Q3 2023, selling an estimated $1.05M.
- Virtus ETF Advisers's ten largest holdings make up 6.1% of its $165M portfolio in Q3 2023.
- Virtus ETF Advisers opened 53 new positions and closed 54 in Q3 2023.
- Virtus ETF Advisers's portfolio value fell 2.4% quarter-over-quarter to $165M.
Based on Virtus ETF Advisers's 13F filing for Q3 2023, filed 7 Nov 2023.